Medication persistence with weekly versus daily doses of orally administered bisphosphonates

Endocrine Practice

Volumn 12, Issue 5, 2006, Pages 522-528

  Ettinger, Mark P ^a   Gallagher, Rich ^b   MacCosbe, Paul E ^c  

^a RADIANT RESEARCH   (United States)

^b Wolters Kluwer   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; RISEDRONIC ACID; DRUG DERIVATIVE; ETIDRONIC ACID;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG USE; FEMALE; HEALTH CARE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHARMACY; PRESCRIPTION; UNITED STATES; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG ADMINISTRATION; EVALUATION; LONG TERM CARE; METHODOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE OSTEOPOROSIS; PSYCHOLOGICAL ASPECT; STATISTICS;

ADMINISTRATION, ORAL; AGED; ALENDRONATE; COHORT STUDIES; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; FEMALE; HUMANS; LONG-TERM CARE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE;

EID: 33947429732     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.12.5.522     Document Type: Article

References (41)

1. Looker AC, Orwoll ES, Johnston CC Jr, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res. 1997;12: 1761-1768.
2. Ettinger MP. Aging bone and osteoporosis: strategies for preventing fractures in the elderly. Arch Intern Med. 2003; 163:2237-2246.
3. National Osteoporosis Foundation. Fast facts. Available at: http://www.nof.org/osteoporosis/diseasefacts.htm. Accessed for verification March 8, 2006.
4. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ. 2003;81:646-656.
5. International Osteoporosis Foundation. Facts and statistics about osteoporosis and its impact. Available at: www.osteofound.org/press_centre/ fact_sheet.html. Accessed for verification March 8, 2006.
6. Hodgson SF, Watts NB, Bilezikian JP, et al (AACE Osteoporosis Task Force). American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003 [erratum in Endocr Pract. 2004;10:90]. Endocr Pract. 2003;9:544-564.
7. American College of Obstetricians and Gynecologists, Women's Health Care Physicians. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists. Obstet Gynecol. 2004;103:203-216.
8. Cheung AM, Feig DS, Kapral M, Diaz-Granados N, Dodin S (Canadian Task Force on Preventive Health Care). Prevention of osteoporosis and osteoporotic fractures in postmenopausal women: recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ. 2004;170:1665-1667.
9. Stafford RS, Drieling RL, Hersh AL. National trends in osteoporosis visits and osteoporosis treatment, 1988-2003. Arch Intern Med. 2004;164:1525-1530.
10. Sebaldt RJ, Shane LG, Pham BZ, et al. Impact of noncompliance and non-persistence with daily bisphosphonates on longer-term effectiveness outcomes in patients with osteoporosis [abstract]. J Bone Miner Res. 2004; 19(Suppl 1):S445. Abstract M423.
11. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004;15: 1003-1008.
12. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004;48:271-287.
13. Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int. 2003;14:965-968.
14. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89:1117-1123.
15. Ryan PJ, Harrison R, Blake GM, Fogelman I. Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis. Br J Obstet Gynaecol. 1992;99:325-328.
16. Ettinger B, Pressman A, Silver P. Effect of age on reasons for initiation and discontinuation of hormone replacement therapy [erratum in Menopause. 2000;7:135]. Menopause. 1999;6:282-289.
17. Ettinger B, Pressman A. Continuation of postmenopausal hormone replacement therapy in a large health maintenance organization: transdermal matrix patch versus oral estrogen therapy. Am J Manag Care. 1999;5:779-785.
18. Kayser J, Ettinger B, Pressman A. Postmenopausal hormonal support: discontinuation of raloxifene versus estrogen. Menopause. 2001;8:328-332.
19. den Tonkelaar I, Oddens BJ. Determinants of long-term hormone replacement therapy and reasons for early discontinuation. Obstet Gynecol. 2000;95:507-512.
20. Ettinger B, Pressman A, Schein J, Chan JK, Silver P, Connolly N. Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Managed Care Pharm. 1998;4:488-492.
21. Faulkner DL, Young C, Hutchins D, McCollam JS. Patient noncompliance with hormone replacement therapy: a nationwide estimate using a large prescription claims database. Menopause. 1998;5:226-229.
22. Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med. 2003;115:209-216.
23. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296-1310.
24. Bone HG, Adami S, Rizzoli R, et al. Weekly administration of alendronate: rationale and plan for clinical assessment. Clin Ther. 2000;22:15-28.
25. Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int. 2002;71:103-111.
26. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis: Alendronate Once-Weekly Study Group. Aging (Milano). 2000;12:1-12.
27. McClung MR. Bisphosphonates in osteoporosis: recent clinical experience. Expert Opin Pharmacother. 2000;1: 225-238.
28. United States Department of Health & Human Services. Bone health and osteoporosis: a report of the surgeon general (2004). Available at: http://www.hhs.gov/surgeongeneral/library/bonehealth/content.html. Accessed for verification March 8, 2006.
29. Recker RR, Weinstein RS, Chesnut CH III, et al. Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int. 2004;15:231-237.
30. Delmas PD, Recker RR, Chesnut CH III, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int. 2004;15: 792-798.
31. Chesnut CH III, Skag A, Christiansen C, et al (Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe [BONE]). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241-1249.
32. Adami S, Felsenberg D, Christiansen C, et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone. 2004;34:881-889.
33. Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res. 2005;20:1315-1322.
34. Segal E, Tamir A, Ish-Shalom S. Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J. 2003;5:859-862.
35. Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J. 2002;95:68-71.
36. Richter A, Anton SE, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes [with discussion]. Clin Ther. 2003;25:2306-2335.
37. Chapurlat RD, Cummings SR. Does follow-up of osteoporotic women treated with antiresorptive therapies improve effectiveness? Osteoporos Int. 2002;13:738-744.
38. DiMatteo MR. Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol. 2004; 23:207-218.
39. Emkey R, Delmas PD, Goemaere S, et al. Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study. Arthritis Rheum. 2003;48:1102-1108.
40. Krueger KP, Felkey BG, Berger BA. Improving adherence and persistence: a review and assessment of interventions and description of steps toward a national adherence initiative [with quiz]. J Am Pharm Assoc (Wash DC). 2003; 43:668-679.
41. Pickney CS, Arnason JA. Correlation between patient recall of bone densitometry results and subsequent treatment adherence. Osteoporos Int. 2005;16:1156-1160.